Literature DB >> 18483912

Comparison of enzyme-linked immunosorbent assay and haemagglutination inhibition test for the detection of antibodies against Newcastle disease virus in ostriches (Struthio camelus).

H F Cadman1, P J Kelly, N D de Angelis, C Rohde, N Collins, T Zulu.   

Abstract

Reactivity of ostrich sera to Newcastle disease virus (NDV) by enzyme-linked immunosorbent assay (ELISA) and haemagglutination inhibition (HI) test were compared. Ten-month old ostriches seronegative by both tests were vaccinated with an oil-based NDV vaccine on days 0 and 11. Significant levels of reactive antibodies were first detected on day 11 by ELISA (sample/positive ratio > 0.2 in 11/20 birds; 55%) and HI (titre > 1/8 in 10/20 birds; 50%). At the end of the experiment (day 37) all birds had significant antibody levels by ELISA, but only 16/20 (80%) by HI test. There was a sigmoidal relationship (r= 0.62, 3rd degree polynomial) between antibody levels detected by ELISA and by HI test. Antibodies reactive with NDV in naturally exposed ostriches from Zimbabwe and Botswana were also detected by ELISA (112/165; 68%) and HI (85/165; 52%).

Entities:  

Year:  1997        PMID: 18483912     DOI: 10.1080/03079459708419218

Source DB:  PubMed          Journal:  Avian Pathol        ISSN: 0307-9457            Impact factor:   3.378


  3 in total

1.  Detection and quantification of antibodies to Newcastle disease virus in ostrich and rhea sera using a liquid phase blocking enzyme-linked immunosorbent assay.

Authors:  R L Moro de Sousa; H J Montassier; A A Pinto
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection.

Authors:  Bin Wang; Bin Wang; Peixin Liu; Tao Li; Wei Si; Jinsheng Xiu; Henggui Liu
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

3.  Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Authors:  Jacob M Ricca; Anton Oseledchyk; Tyler Walther; Cailian Liu; Levi Mangarin; Taha Merghoub; Jedd D Wolchok; Dmitriy Zamarin
Journal:  Mol Ther       Date:  2018-01-31       Impact factor: 11.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.